High Expression of Class III β-tubulin in Upper Gastrointestinal Cancer Types

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Dec 15

PMID 30546449

Citations 7

Authors

Doris Hoflmayer

Eray Ozturk

Cornelia Schroeder

Claudia Hube-Magg

Niclas C Blessin

Ronald Simon

Dagmar S Lang

Emily Neubauer

Cosima Gobel

Marie-Christine Heinrich

Christoph Fraune

Katharina Moller

Moritz Armbrust

Morton Freytag

Andrea Hinsch

Clara Luhr

Magdalena Noack

Viktor Reiswich

Soren Weidemann

Maximilian Bockhorn

Daniel Perez

Jakob R Izbicki

Guido Sauter

Frank Jacobsen

Affiliations

Soon will be listed here.

Abstract

Class III β-tubulin (TUBB3) is a component of microtubules of neuronal cells that is upregulated in various cancer entities. To better understand the role of TUBB3 in upper gastrointestinal tract cancer types, the present study assessed TUBB3 expression in tissue microarrays including 189 gastric and 428 esophageal cancer. TUBB3 expression was detected in 62.4% of gastric cancer, 73.8% of esophageal adenocarcinoma and 88.7% of esophageal squamous cell cancer, while control samples of normal esophageal and gastric epithelium were TUBB3-negative. TUBB3 positivity was not associated with the International Union Against Cancer classification, World Health Organization grading, lymph node involvement or distant metastasis in any entity. Of note, TUBB3 expression was associated with tumor localization and prognosis in gastric cancer, with the tumor stage in esophageal adenocarcinoma, and with the resection margin in esophageal squamous cell cancer. In conclusion, the substantial rate of positivity for TUBB3 already in early stages of gastric cancer in combination with the lack of a further increase in frequency with tumor stage, may suggest, that TUBB3 upregulation is rather relevant for cancer development than for cancer progression. TUBB3 might be a suitable prognostic biomarker in gastric cancer types.

Citing Articles

Sox2 and βIII-Tubulin as Biomarkers of Drug Resistance in Poorly Differentiated Sinonasal Carcinomas.

Lopez L, Fernandez-Vanes L, Cabal V, Garcia-Marin R, Suarez-Fernandez L, Codina-Martinez H J Pers Med. 2023; 13(10).

PMID: 37888115 PMC: 10608336. DOI: 10.3390/jpm13101504.

Dissection of molecular and histological subtypes of papillary thyroid cancer using alternative splicing profiles.

Park J, Kim D, Lee J, Park H, Ryu B, Kim J Exp Mol Med. 2022; 54(3):263-272.

PMID: 35277656 PMC: 8980103. DOI: 10.1038/s12276-022-00740-0.

Molecular mechanisms associated with chemoresistance in esophageal cancer.

Lohan-Codeco M, Barambo-Wagner M, Nasciutti L, Pinto L, Meireles Da Costa N, Palumbo Jr A Cell Mol Life Sci. 2022; 79(2):116.

PMID: 35113247 PMC: 11073146. DOI: 10.1007/s00018-022-04131-6.

The phosphatase of regenerating liver-3 protein (PRL-3) promotes glioma cell invasiveness by interacting with β3 -tubulin.

Ge Z, Gu T, Zhang L, Fan Q, Ma L, Fang N Bioengineered. 2022; 13(2):4112-4121.

PMID: 35098869 PMC: 8973939. DOI: 10.1080/21655979.2021.2001220.

Identification of cholinergic cells with chemosensory traits in the porcine uterus.

Sponchiado M, Liao Y, Reznikov L Cell Tissue Res. 2022; 388(1):33-47.

PMID: 35084573 PMC: 11441723. DOI: 10.1007/s00441-022-03585-1.

References

. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636):169-175. PMC: 5651175. DOI: 10.1038/nature20805. View

Kavallaris M, Kuo D, Burkhart C, Regl D, Norris M, Haber M . Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997; 100(5):1282-93. PMC: 508306. DOI: 10.1172/JCI119642. View

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M . Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014; 20(38):13842-62. PMC: 4194567. DOI: 10.3748/wjg.v20.i38.13842. View

Ranganathan S, Benetatos C, Colarusso P, Dexter D, Hudes G . Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer. 1998; 77(4):562-6. PMC: 2149944. DOI: 10.1038/bjc.1998.91. View

Cao Y, Zhang G, Wang P, Zhou J, Gan W, Song Y . Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol. 2017; 17(1):2. PMC: 5217235. DOI: 10.1186/s12876-016-0561-x. View

Zhang H, Ruan L, Zheng L, Whyte D, Tzeng C, Zhou X . Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2012; 77(1):9-15. DOI: 10.1016/j.lungcan.2012.01.005. View

Yang Y, Luo X, Xian L . The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. PLoS One. 2014; 9(4):e93997. PMC: 3976369. DOI: 10.1371/journal.pone.0093997. View

Falconer M, Echeverri C, Brown D . Differential sorting of beta tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. Cell Motil Cytoskeleton. 1992; 21(4):313-25. DOI: 10.1002/cm.970210407. View

Katsetos C, Herman M, Mork S . Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton. 2003; 55(2):77-96. DOI: 10.1002/cm.10116. View

10.

Matsuda T, Saika K . The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2013; 43(11):1157-8. DOI: 10.1093/jjco/hyt166. View

11.

Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S . Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008; 21(11):1371-8. DOI: 10.1038/modpathol.2008.104. View

12.

Yu Y, Ding S, Liang Y, Zheng Y, Li W, Yang L . Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis. Exp Ther Med. 2014; 7(6):1578-1582. PMC: 4043588. DOI: 10.3892/etm.2014.1659. View

13.

Urano N, Fujiwara Y, Doki Y, Kim S, Miyoshi Y, Noguchi S . Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol. 2006; 28(2):375-81. View

14.

Horak C, Pusztai L, Xing G, Trifan O, Saura C, Tseng L . Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res. 2013; 19(6):1587-95. DOI: 10.1158/1078-0432.CCR-12-1359. View

15.

Burkhart C, Kavallaris M, Band Horwitz S . The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta. 2001; 1471(2):O1-9. DOI: 10.1016/s0304-419x(00)00022-6. View

16.

Hinsch A, Chaker A, Burdelski C, Koop C, Tsourlakis M, Steurer S . βIII-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Hum Pathol. 2016; 61:210-220. DOI: 10.1016/j.humpath.2016.11.005. View

17.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos A, Beau-Faller M . High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther. 2012; 11(5):1203-13. DOI: 10.1158/1535-7163.MCT-11-0899. View

18.

Lewis S, Lee M, Cowan N . Five mouse tubulin isotypes and their regulated expression during development. J Cell Biol. 1985; 101(3):852-61. PMC: 2113702. DOI: 10.1083/jcb.101.3.852. View

19.

Zhang Y . Epidemiology of esophageal cancer. World J Gastroenterol. 2013; 19(34):5598-606. PMC: 3769895. DOI: 10.3748/wjg.v19.i34.5598. View

20.

Tsourlakis M, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T . βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol. 2014; 184(3):609-17. DOI: 10.1016/j.ajpath.2013.11.007. View